Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9343653 | 0.91 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL9194936 | 0.91 | — | — | |
| SCHEMBL9262491 | 0.89 | AGTR1 (0.44) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL9199639 | 0.87 | AGTR1 (0.56) | AGTR1AGTR2 | |
| Losartan SCHEMBL60 | 0.87 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL6092394 | 0.87 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL29383742 | 0.87 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL3216357 | 0.86 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL42080 | 0.86 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL17653794 | 0.86 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0540400-B1 | Quinoline derivatives, useful as angiotensin II antagonists | SYNTHELABO (FR) | 1995-08-23 | — | — | EP | claimed |
| US-5371227-A | Quinoline derivatives, process for their preparation, and their therapeutic applications | SYNTHELABO (FR) | 1994-12-06 | — | — | US | claimed |
| EP-0569013-A1 | Quinoline compounds as angiotensin II antagonists | THE GREEN CROSS CORPORATION (JP) | 1993-11-10 | — | — | EP | claimed |
| EP-0540400-A1 | Quinoline derivatives, useful as angiotensin II antagonists | SYNTHELABO (FR) | 1993-05-05 | — | — | EP | claimed |
| US-5665881-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVE, ANGIOTENSIN II ANTAGONIST | THE GREEN CROSS CORPORATION (JP) | 1997-09-09 | — | — | US | disclosed |
| EP-0693478-A1 | Quinoline compounds | THE GREEN CROSS CORPORATION (JP) | 1996-01-24 | — | — | EP | disclosed |
| US-5478832-A | Angiotensin II antagonists; cardiovascular disorders | THE GREEN CROSS CORPORATION (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0540400-B1 | Quinoline derivatives, useful as angiotensin II antagonists | SYNTHELABO (FR) | 1995-08-23 | — | — | EP | disclosed |
| US-5432283-A | Substituted phenyl in 2 position; intermediates for drugs to treat hypertensive pathologies, cardiac, renal or pulmonary insufficiencies, and glaucoma | SYNTHELABO (FR) | 1995-07-11 | — | — | US | disclosed |
| US-5371227-A | Quinoline derivatives, process for their preparation, and their therapeutic applications | SYNTHELABO (FR) | 1994-12-06 | — | — | US | disclosed |
| EP-0569013-A1 | Quinoline compounds as angiotensin II antagonists | THE GREEN CROSS CORPORATION (JP) | 1993-11-10 | — | — | EP | disclosed |
| EP-0540400-A1 | Quinoline derivatives, useful as angiotensin II antagonists | SYNTHELABO (FR) | 1993-05-05 | — | — | EP | disclosed |